, Wen-Hsin Huang
, Hsing-Hung Cheng
Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
© 2025 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Malignant disease | Benign disease |
|---|---|
| Pancreatic cancer | Peptic ulcer disease |
| Bile duct cancer | Acute pancreatitis |
| Gallbladder cancer | Chronic pancreatitis |
| Ampulla of Vater cancer | Caustic ingestion |
| Gastric cancer | Crohn’s disease |
| Duodenal cancer | Postendoscopic therapy |
| Postradiotherapy | |
| Metastatic tumor or lymph nodes | Superior mesenteric syndrome |
| Miscellaneous |
| LAMS | Hot AXIOS | Hot-Spaxus | Z-EUS IT (Hanarostent Plumber) | Novel LAMS | Nagi | Aixstent |
|---|---|---|---|---|---|---|
| Manufacturer | Boston Scientific; Natick, MA, USA | Taewoong Medical; Gimpo, Korea | M.I Tech; Pyeongtaek, Korea | Micro-Tech Co., Ltd.; Nanjing, China | Taewoong Medical; Gimpo, Korea | Leufen Medical; Berlin, Germany |
| Flange diameter (mm) | 14, 17, 21, 24, 29 | 23, 25, 31 | 22, 24, 26, 28 | 20-26 | 20 | 25 |
| Length (mm) | 8, 10, 15 | 20 | Total length: 20, 30, 40 | 20 | 10, 20, 30 | 30 |
| Usable length: 13, 23, 33 | ||||||
| Length diameter (mm) | 6, 8, 10, 15, 20 | 8, 10, 16 | 10, 12, 14, 16 | 12–16 | 10, 12, 14, 16 | 10, 15 |
| Delivery Catheter (Fr) | 9, 10.8 | 10 | 10.5 | 9, 10.5 | 9, 10 | 10 |
| Electrocautery tip | Yes | Yes | Yes | Yes | No | No |
| Study | Type of study | No. of sizes (n) | Etiology | Technique | Type of LAMS | Diameter of LAMS (mm) | Technical success (%) | Clinical success (%) | AE (%) | Detail of AEs | Recurrent GOO (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Khashab et al. (2015)14 | Multicenter, retrospective | 10 | Malignant, n=3; benign, n=7 | Direct, n=1; balloon-assisted, n=9 | NEC LAMS (AXIOS) | 15×10 | 90 | 90 | 0 | 0 | 0 |
| Itoi et al. (2016)46 | Single center, prospective | 20 | Malignant, n=20 | EPASS, n=20 | EC LAMS (Hot AXIOS) | 15×10 | 90 | 90 | 10 | Misdeployment and pneumoperitoneium, n=2 | 0 |
| Tyberg et al. (2016)15 | International multicenter, retrospective | 26 | Malignant, n=17; benign, n=9 | Direct, n=3; balloon-assisted, n=13; nasobiliary drain, n=3; USE-assisted, n=5; NOTES, n=2 | NEC LAMS, n= 17 | 15×10, n=25; 10×10, n=1 | 92 | 85 | 11.5 | Peritonitis, n=1; bleeding, n=1; abdominal pain, n=1 | 0 |
| EC LAMS (Hot AXIOS), n= 9 | |||||||||||
| Chen et al. (2017)25 (EUS-GE vs. ES) | International multicenter, retrospective | 30 | Malignant, n=30 | Direct, n=2; balloon-assisted, n=6; EPASS, n=22 | EC LAMS (Hot AXIOS), n=20; NEC LAMS (AXIOS), n=7; NECL LAMS (Spaxus), n=2 | 15×10 | 86.7 | 83.3 | 10 | Misdeployment, n=3 | 4.3 |
| Perez-Miranda et al. (2017)26 (EUS-GE vs. SGJ) | Multicenter, retrospective | 25 | Malignant, n=17; benign, n=8 | Direct, n=6; balloon-assisted, n=9; USE-assisted, n=7; nasobiliary drain, n=3 | EC LAMS (Hot AXIOS), NEC LAMS (AXIOS) | NA | 88 | 84 | 12 | Bleeding, n=2; peritonitis, n=1 | 0 |
| Khashab et al. (2017)27 (EUS-GE vs. SGJ) | International multicenter, retrospective | 30 | Malignant, n=30 | Direct, n=2; balloon-assisted, n=6; EPASS, n=22 | EC LAMS (Hot AXIOS), n=21; NEC LAMS (AXIOS), n=7; NEC LAMS (Spaxus), n=2 | NA | 87 | 87 | 16 | Misdeploymenet, n=3; abdominal pain, n=2 | 3 |
| Chen et al. (2018)16 | International multicenter, retrospective | 26 | Benign, n=26 | Direct, n=15; balloon-assisted, n=7; EPASS, n=4 | NEC LAMS, n=2; EC LAMS (Hot AXIOS), n=24 | 15×10 | 96 | 84 | 11.5 | Misdeployment, n=2; gastric leakage, n=1 | 4.8 |
| Chen et al. (2018)17 | Multicenter, retrospective | 74 | Malignant, n=49; benign, n=25 | Direct, n=52; balloon-assisted, n=22 | NEC LAMS, n=14; EC LAMS (Hot AXIOS), n=59 | 15×10 | 93.2 (direct, 94.2%; balloon-assisted, 90.9%) | 91.9 (direct: 92.3%; balloon-assisted, 90.9%) | 6.8 (direct: 5.8%; balloon-assisted, 9.1%) | Misdeployment, n=5 | 9.5 |
| Ge et al. (2019)28 (EUS-GE vs. ES) | Single center, retrospective | 22 | Malignant, n=22 | Direct, n=22 | EC LAMS (Hot AXIOS) | 15×10 | 100 | 96 | 18.1 | Misdeployment, n=2; LAMS mesh erosion, n=1; stent ingrowth, n=1 | 4.5 |
| Kerdsirichairat et al. (2019)18 | Single center, retrospective | 57 | Malignant, n=34; benign, n=23 | Direct, n=57 | EC LAMS (Hot AXIOS) | 15×10 | 92.9 | 89.5 | 3.5 | Leakage, n=1; hemoperitoneium, n=1 | 15.1 |
| James et al. (2020)19 | Single center, retrospective | 22 | Benign, n=22 | Direct, n=9; balloon-assisted, n=8; orojejunal, n=5 | NEC LAMS, EC LAMS (Hot AXIOS) | 15×10, n=16; 20×10, n=5 | 95.4 | NA | 19 | Abdominal pain, n=1; bleeding, n=1; stent migration, n=1; necrotizing pancreatitis, n=1 | 23.8 |
| Kastelijn et al. (2020)29 | International multicenter, retrospective | 45 | Malignant, n=45 | Direct, n=36; balloon-assisted, n=9 | EC LAMS (Hot AXIOS) | 15×10, n=32; 20×10, n=12 | 86.7 | 73.3 | 26.7 | Misdeploymenet, n=5; infection, n=6; stent dislocation, n=1 | 6.1 |
| Xu et al. (2020)49 | Single center, retrospective | 36 | Malignant, n=36 | EPASS, n=36 | EC LAMS |
NA | 100 | 94.4 | 25 | Misdeploymenet, n=1; bleeding, n=2; metal stent cutting the guidewire, n=3; stent migration, n=2; peritonitis, n=3; delayed bleeding, n=2 | 2.7 |
| Wannhoff et al. (2021)20 | Single center, retrospective | 35 | Malignant, n=33; benign, n=2 | Direct, n=22; nasobiliary, n=10; others, n=2 | NEC LAMS (Spaxus; HANARO), EC LAMS (Hot AXIOS) | Hot AXIOS, n=31; 10×10, n=1; 15×10, n=18; 20×10, n=12; Niti-S Spaxus, 16×20, n=2; HANARO, 16×40, n=1 | 80 | 74.3 | 14.3 | Peritonitis, n=3; perforation, n=1; misdeployment, n=1 | NA |
| Bronswijk et al. (2021)37 (EUS-GE vs. SGJ) | International multicenter, retrospective | 77 | Malignant, n=74; benign, n=3 | Nasobiliary, n=77 | EC LAMS (Hot AXIOS) | NA | 94.8 | 92.2 | 6.5 | Misdeployment, n=2; fever, n=2; sepsis, n=1 | 0 |
| Havre et al. (2021)38 | Single center, retrospective | 33 | Malignant, n=28; benign, n=5 | Nasobiliary, n=33 | EC LAMS (Hot AXIOS) | 15×10, n=22; 20×10, n=7 | 100 | 0.91 | 30 | Stent migration, n=3; bleeding, n=2; pneumonia, n=3; refeeding syndrome, n=1; more puncture, n=1 | 0 |
| Jovani et al. (2021)21 | Single center, retrospective | 73 | Malignant, n=64; benign, n=9 | Direct, n=73 | EC LAMS (Hot AXIOS) | 15×10, n=64; 20×10, n=4 | 93 (68/73) | 97 (66/68) | 7.4 | Misdeployment, n=3; hemoperitoneium, n=1; stent migration, n=1 | 15 |
| Sobani et al. (2021)31 | Single center, retrospective | 31 | Malignant, n=23; benign, n=8 | Balloon-assisted, n=31 | EC LAMS (Hot AXIOS) | 20×10 | 100 | 93.5 | 3.2 | Bleeding, n=1 | 0 |
| Basha et al. (2021)33 | Single center, retrospective | 31 | Malignant, n=29; benign, n=2 | EPASS, n=27; nasobiliary, n=4 | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 90.3 (ascites, 91.6%; without ascites, 89.4%) | 87.1 (ascites, 83.3%; without ascites, 89.4%) | 6.4 (ascites, 0%; without ascites, 10.5%) | Colonic perforation, n=1; bleeding, n=1 | NA |
| Nguyen et al. (2021)34 | Single center, retrospective | 42 | Malignant, n=35; benign, n=7 | oroenteric catheter-assisted | EC LAMS (Hot AXIOS) | 15×10 | 98 | 93 | 7 | Misdeployment, n=1; stent occlusion, n=2 | NA |
| Bejjani et al. (2022)22 | International multicenter, retrospective | 267 | Malignant, n=267 | Direct, balloon-assisted | EC LAMS (Hot AXIOS) | 15×10, n=148; 20×10, n=119 | 95.5 (15-mm LAMS, 96%; 20-mm LAMS, 95%) | 87 (15-mm LAMS, 89.2%; 20-mm LAMS, 84.1%) | 12.4 (15-mm LAMS, 12.8%; 20-mm LAMS, 11.8%) | Misdeployment, n=23; aspiration pneumonia, n=3; small-bowl perforation, n=2; shock/bacteremia, n=2; peritonitis, n=1; others, n=2 | 1.9 (5/267) |
| Abbas et al. (2022)45 | Single center, prospective | 50 | Malignant, n=50 | USE-assisted | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 100 | 92 | 4 | LAMS dislodgement, n=1; gastro-colonic fistula, n=1 | 16 |
| Sánchez-Aldehuelo et al. (2022)39 (EUS-GE vs. ES) | Multicenter, retrospective | 79 | Malignant, n=79 | Nasobiliary, n=79 | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 93.7 | 92.4 | 10.1 | Misdeployment, n=3; bleeding, n=2; perforation, n=1; severe pain, n=1; aspiration, n=1 | 2.5 (2/79) |
| Fischer et al. (2022)40 | Two-center, retrospective | 45 | Malignant, n=39; benign, n=4; unclear, n=2 | USE-assisted, n=18; nasobiliary, n=27 | EC LAMS (Hot AXIOS) | 10×10, n=1; 15×10, n=14; 20×10, n=30 | 98 | 95 | 24 | Stent misplacement, n=7; bleeding, n=2; leakage, n=1; gastrojejunocolic fistula, n=1 | 18 |
| Choi et al. (2022)41 | Single center, retrospective | 52 | Malignant, n=41; benign, n=11 | Endoscope-assisted nasobiliary | NEC LAMS (AXIOS), n=6; EC LAMS (Hot AXIOS), n=46 | 10×10, n=3; 15×10, n=47; 20×10, n=1 | 92.3 | 80.8 | 26.9 | Misdeployment, n=7; pneumoperitoneium, n=2; migration, n=1; miscellaneous, n=4 | 17.3 |
| Mahmoud et al. (2022)30 | Single center, retrospective | 55 | Malignant, n=55 | Direct, n=7; dual scope assisted, n=10; balloon-assisted, n=8; nasobiliary, n=30 | NEC LAMS (AXIOS), n=1; EC LAMS (Hot AXIOS), n=54 | NA | 94.8 (55/58) | 91.7 (51/55) (ascites, 91.7%; without ascites, 93.5%) | 27.2 (15/55) (ascites, 37.5%; without ascites, 19.4%) | Misdeployment, n=5; stent migration, n=1; abdominal pain, n=5; DVT, n=1; tissue ingrowth, n=1; cholangitis, n=1; peritonitis, n=2; sepsis, n=2 | 3.6 |
| Perez-Cuadrado-Robles et al. (2022)42 | Single center, retrospective | 28 | Malignant, n=28 | Oroenteric catheter-assisted | EC LAMS (Hot AXIOS) | 20×10 | 89.3 | 88 | 7.1 | Gastrocolic fistula, n=1; colonic perforation, n=1 | 18.2 |
| van Wanrooij et al. (2022)32 (EUS-GE vs. ES) | International multicenter, retrospective | 107 | Malignant, n=107 | Nasobiliary | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 94 | 91 | 10.2 | Misdeployment, n=3; aspiration pneumonia, n=1; cholangits, n=3; bleeding, n=1 | 1 |
| Garcia-Alonso et al. (2023)43 | Multicenter, prospective | 64 | Malignant, n=64 | Nasobiliary | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 98.4 | 83.3 | 15.6 | Bleeding, n=2; perforation, n=2; stent dysfunction, n=1; bacteremia, n=1; aspiration pneumonia, n=1 | 15.2 |
| Chan et al. (2023)50 (EUS-GE vs. ES vs. SGJ) | Two-center, retrospective | 30 | Malignant, n=30 | EPASS, n=30 | EC LAMS (Hot AXIOS) | 15×10, 20×10 | 93.3 | 93.3 | 6.7 (2/30) | Misdeployment, n=1; biliary obstruction, n=1 | 1 |
| Monino et al. (2023)23 | Multicenter, retrospective | 71 | Malignant, n=57; benign, n=14 | Direct, n=30; nasojejunal draing, n=41 | EC LAMS (Hot AXIOS) | 20×10 | 85.9 (WEST, 95.1%; DTOG, 73.3%) | 94.1 (WEST, 97.5; DTOG, 89.3%) | 28.2 (WEST, 14.6%; DTOG, 46.7%) | Misdeployment, n=8; abdominal pain, n=5; vomiting, n=2; delayed bleeding, n=1; peritonitis, n=3; infection, n=3; stent occlusion, n=2; perforation, n=1; LAMS migration, n=1; gastrocolonic–jejunal fistula, n=1; massive jejunalischemia, n=1 | NA |
| Mangiavillano et al. (2023)35 | Multicenter, retrospective | 25 | Malignant, n=22; benign, n=3 | Nasobiliary, n=25 | EC LAMS (Hot-Spaxus) | 10×20, n=5; 16×20, n=20 | 100 | 68 | 0 | 0 | NA |
| Rai et al. (2023)36 | Single center, retrospective | 30 | Malignant, n=26; benign, n=4 | Nasojejunal tube-assisted, n=30 | EC LAMS (Hot AXIOS) | 20×10 | 96.7 (29/30) | 100 (29/29) | 6.7 | Bleeding, n=1; stent migration, n=1 | NA |
| Kahaleh et al. (2024)44 | International multicenter, retrospective | 103 | Malignant, n=72; benign, n=31 | Direct, balloon-assisted, | NEC LAMS (Axios), n=25; EC LAMS (Hot AXIOS), n=78 | 15×10, n=36; 20×10, n=67 | 82.5 (malignant, 83%; benign, 80.6%) | 81.6 (malignant, 83%; benign, 77.4%) | Immediate AE, 11.6% (malignant, 11%; benign, 13%); short-term AE, 19.4% (malignant, 15.2%; benign, 29%) | Misdeployment, n=2; infection, n=5; abdominal pain, n=3; bacterial peritonitis, n=5; ascites infection, n=1; | NA |
| USE-assisted, nasobiliary | GI bleeding, n=2; retroperitoneal abscess, n=1; LAMS-related jejunal ulcer with bleeding, n=1; pneumoperitoneium, n=1; perforation, n=2; hypotension, n=2; secondary obstruction, n=2 | ||||||||||
| On et al. (2023)24 | Multicenter, retrospective | 25 | Malignant, n=22; benign, n=3 | Direct, n=18; orojejunal tube, n=7 | EC LAMS (Hot AXIOS), n=25 | 15×10, n=4; 20×10, n=21 | 92 (23/25) | 100 (23/23) | 8 | Misdeployment, n=2 | 4.8 |
LAMS, lumen-apposing metal stent.
LAMS, Lumen-apposing metal stents; AE, adverse event; GOO, gastric outlet obstruction; NEC, non-electrocautery; EPASS, endoscopic ultrasound-guide double-balloon-occluded gastrojejunostomy bypass; EC, electrocautery; USE, ultraslim endoscope; NOTES, natural orifice transluminal endoscopic surgery; NA, not applicable; EUS-GE, endoscopic ultrasound-guided gastroenterostomy; ES: endoscopic stenting; SGJ, surgical gastrojejunostomy; WEST, wireless endoscopic simplified technique; DTOG, direct technique over a guidewire. EC LAMS: A novel LAMS with an electrocautery tip was made by Micro-Tech Co., Ltd., Nanjing, China.
